May 1, 2025 7:44am

Market and sector volatility persist as equity indexes bounced back closing mixed on Wednesday

3 earnings released, 2 new LPS (loss-per-shares) and a net income (MDXG)

Breaking: First-time filings for unemployment insurance totaled a seasonally adjusted 241 K for the week ended April 26, up 18 K from the prior period and higher than the estimate for 225 K. Continuing claims, which run a week behind and provide a broader view of layoff trends, rose to 1.92 M, up 83 K to the highest level since 11/13/21.

Pre-open Indications: 1 Negative and 3 Positive

Q1/25 earnings: ALNY, MRNA and BPMC on 5/1,

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Wednesday’s night’s … RegMed Investors (RMi) Closing Bell: the sector breathes as canary-in-the coal-mine flaps its wings … https://www.regmedinvestors.com/articles/13900

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), The latest, WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies??? … Newest happening, public accountants walk … https://www.regmedinvestors.com/articles/13812

 

Thursday: The pre-open Dow futures are UP +0.79% or (+322 points), the S&P futures are UP +1.15% or (+64 points) and the Nasdaq futures are UP +1.75% or (+343 points)

  • Stock market futures rose Thursday, 5/1
  • European markets closed for May Day,
  • Most Asian markets closed for holiday, while Japanese and Australian markets rise

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Wednesday: The Dow closed UP +141.74 points or +0.35%, the S&P closed UP +8.23 points or +0.15% while the Nasdaq closed DOWN -14.98 points or -0.09%

Tuesday: The Dow closed UP +300.03 points or +0.75%, the S&P closed UP +32.04 points or +0.58% while the Nasdaq closed UP +95.18 points or +0.55%

Monday: The Dow closed UP +114.09 points or +0.28%, the S&P closed UP +3.54 points or +0.06% while the Nasdaq closed DOWN -16.81 points or -0.10%

Economic Data Docket: weekly jobless claims data and a reading on the U.S. manufacturing sector.

               

Q2 – May – 1st session

  • Q2 - April – 10 negative and 11 positive closes

Q1/25

  • March, 10 positive and 11 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty

Although:

Negative indications:

  • Moderna (MRNA) closed up +$0.72 after Tuesday’s +$0.36 after Monday’s +$0.24 with a negative -$0.40 or -1.40% pre-open with earnings today

Positive Indications:

  • Alnylam Pharmaceuticals (ALNY) closed up +$6.05 after Tuesday’s +$2.34 after Monday’s +$3.29 with a positive +$2.26 or +0.86% pre-open
  • Blueprint Medicine (BPMC) closed up +$1.02 with a positive +1.50 or +1.68% pre-open; earnings report a net income.
  • uniQure NV (QURE) closed up +$0.90 after Tuesday’s -$0.11 with a positive +$0.17 or +1.15% pre-open

 

The BOTTOM LINE: Cell and gene Therapy sector equities stocks bounced back from steep early losses to end in a positive close, continuing their wild swings.

The last week of April and Q1; Tuesday and Monday closed negative …

Last week, the cell and gene therapy sector dived on Friday after bounding on Thursday, Wednesday, Tuesday and Monday.

  • After hints of de-escalation of U.S.-China trade tensions brought buyers in from the sidelines and after President Trump said he has no plans to fire Fed Chair Powell.

Friday initiated a solid weekly performance for the market; the S&P 500 is up +3.8% and Nasdaq +5.4% and the Dow +2%.

 

The earnings’ downdraft begins to happen next week!

 

Brace ourself for more economics and their down trending affect?

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.